Cargando…

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients

BACKGROUND: Protection offered by coronavirus disease 2019 (COVID-19) vaccines wanes over time, requiring an evaluation of different boosting strategies to revert such a trend and enhance the quantity and quality of Spike-specific humoral and cellular immune responses. These immunological parameters...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khoo, Nicholas Kim Huat, Lim, Joey Ming Er, Gill, Upkar S., de Alwis, Ruklanthi, Tan, Nicole, Toh, Justin Zhen Nan, Abbott, Jane E., Usai, Carla, Ooi, Eng Eong, Low, Jenny Guek Hong, Le Bert, Nina, Kennedy, Patrick T.F., Bertoletti, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Inc. 2022
Materias:	Clinical and Translational Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767655/ https://www.ncbi.nlm.nih.gov/pubmed/35072129 http://dx.doi.org/10.1016/j.medj.2021.12.004

Ejemplares similares

Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
por: de Alwis, Ruklanthi, et al.
Publicado: (2020)

BNT162b2 mRNA Vaccine–Induced Immune Response in Oral Fluids and Serum
por: Seneviratne, Chaminda Jayampath, et al.
Publicado: (2022)

Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine
por: Tschismarov, Roland, et al.
Publicado: (2021)

SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8(+) and CD4(+) T cells of broad specificity
por: Lim, Joey Ming Er, et al.
Publicado: (2022)

Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination
por: Ooi, Eng Eong, et al.
Publicado: (2022)

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
por: Kalimuddin, Shirin, et al.
Publicado: (2021)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells
por: Saron, Wilfried A. A., et al.
Publicado: (2018)

Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
por: Zhu, Yufang, et al.
Publicado: (2022)

Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
por: Oh, Bernice Ling Zhi, et al.
Publicado: (2022)

Asymptomatic SARS-CoV-2 infection
por: Ooi, Eng Eong, et al.
Publicado: (2020)

Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
por: Tan, Anthony T., et al.
Publicado: (2022)

A Dynamic Immune Response Shapes COVID-19 Progression
por: Ong, Eugenia Ziying, et al.
Publicado: (2020)

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
por: Fournillier, Anne, et al.
Publicado: (2013)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
por: Lyke, Kirsten E., et al.
Publicado: (2023)

The re-emergence of dengue in China
por: Ooi, Eng Eong
Publicado: (2015)

A tribute to the late Emeritus Professor Chan Soh Ha
por: Ooi, Eng Eong
Publicado: (2021)

Current Status of Dengue Therapeutics Research and Development
por: Low, Jenny G. H., et al.
Publicado: (2017)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
por: Cheng, Haoyue, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial
por: Kalimuddin, Shirin, et al.
Publicado: (2023)

Characteristics of acute febrile illness and determinants of illness recovery among adults presenting to Singapore primary care clinics
por: Tun, Zaw Myo, et al.
Publicado: (2016)

The identification of novel immunogenic antigens as potential Shigella vaccine components
por: de Alwis, Ruklanthi, et al.
Publicado: (2021)

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
por: Venkatraman, Navin, et al.
Publicado: (2019)

Patterns of medication use and factors associated with antibiotic use among adult fever patients at Singapore primary care clinics
por: Tun, Zaw Myo, et al.
Publicado: (2016)

Evolution of Subgenomic RNA Shapes Dengue Virus Adaptation and Epidemiological Fitness
por: Finol, Esteban, et al.
Publicado: (2019)

Minding the “T”s beyond the “B”s: Shaping vaccines for future pandemics
por: Kalimuddin, Shirin, et al.
Publicado: (2023)

On the Recent Advances in the Theory of Vision
por: Helmholtz, H., et al.
Publicado: (1872)

On the Recent Advances in the Theory of Vision
por: Helmholtz, H., et al.
Publicado: (1872)

On the Recent Advances in the Theory of Vision
por: Helmholtz, H., et al.
Publicado: (1872)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
por: Liu, Xiaoqiang, et al.
Publicado: (2022)

Oxygen: viral friend or foe?
por: Gan, Esther Shuyi, et al.
Publicado: (2020)

Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine
por: Ong, Eugenia Z., et al.
Publicado: (2022)

Adverse effects following anti–COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes
por: Syenina, Ayesa, et al.
Publicado: (2022)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Pre‐existing heterologous T‐cell immunity and neoantigen immunogenicity
por: Leng, Qibin, et al.
Publicado: (2020)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
por: Liu, W M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_govl1go8td8vsqt5vj9mu44lqk